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PROGRAM OVERVIEW: DISEASES TREATED, TYPES OF TRANS- 
PLANTS, REGIMENS AND OUTCOMES IN AN OUTPATIENT BLOOD 
AND MARROW TRANSPLANT PROGRAM 
WilsoT~, 3/I.C.1; Ki~g, j.i; Scott, L.3/IJ; Pien'e, 7~1x£1; Shamlou, R.1; 
Sa1"aci*~o, G.e; HG3ite, M.t; Agura, E.D.l; Bev'vymmz, R.B.~; Fay, 
J. FFJ; Pkzeivo, L.l; ~'Smce, E.A. I 1. Baylor-$'am'molTs Cgmcev Center 
and Texas Oncology, P.A., Dallas, TX; 2. Baylov UTdvevsity ~>iedical 
Cezltel', Drdlas, TX. 
The Blood and Marrow Transplant program at US Oncology at 
Baylor University Medical Center in Dallas, TX expanded its out- 
patient facility in May 2002 to a 14, 000 square foot facility with 
16 infnsion chairs, 6 private rooms and 15 exam rooms. The out- 
patient clinic is open 7 days a week, from 8 AM until 7PM. There 
are 5 attending physicians, 10 infusion nurses, 5 transplant coordi- 
nators, 1 pharmacist, pharmacy technicians and numerous admin- 
istrative support personnel. The outpatient clinic has its own 
pharmacy infusion satellite and offers laboratory selwices. In 2001, 
we performed 168 total transplants with 26 (15%) of those being 
initiated on an outpatient basis. In 2002, year to date, we have per- 
formed a total of 109 transplants, with 25 (23 %) of patients being 
done primarily on an outpatient basis. Of the 25 patients treated 
in 2002, the diseases include AML (2), MDS (1), CML (1), 
Hodgkin's Disease (2), Multiple Myeloma (4), NHL (1~), Ovarian 
(1) and Waldenstrom's Macroglobulinemia (1). There were 17 
autologous transplants, 3 allogeneic sibling transplants, and 5 
lnatched-unrelated donor transplants done on an outpatient basis. 
The preparative regimens used in the outpatient transplants 
include BEAM (8), Melphalan (5), ThioTepa/TBI (2), BUS/CTX 
(2), Carbo/TT (1), and CTX/TBI (1). Six patients received non- 
ablative transplants using Flud/TBI (5) and Flud/CTX (1). Of the 
25 outpatients reated, 12 (48%) had to be admitted within the 
first 30 days of transplant for a median of 3 days. The primary rea 
sons for admission include mucositis, nausea/vomiting and febrile 
neutropenia. There were 23 of 25 patients (92%) alive at Day 90 
post transplant. Of the patients treated in 2002, there have been 2 
deaths, 1 due to complications of recurrent AML, and 1 due to 
graft-versus-host-disease. When appropriate resources are avail- 
able, outpatient transplants can be safe and effective in selected 
patients. 
ALT before transplant may be highly predictive of early toxic 
death after IISCT. At our institution, Bu/Cy regimen was used 
frequently and may be related to these results. 
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VALACYCLOVIR COMPARED TO ACYCLOVIR FOR 
CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC STEM CELL 
TRANSPLANTS RECIPIENTS 
Artz, A.S4 Dieter/e, N.; Gekns, J.; Pm-snd, S'., l,arsol~, R.; Stock, k~; 
Da/ighevty, C.; Zimme'lwla*z, T.; Odemke, 0.; Smith, S.; ITmz Besie*l, 
K. Hematolog/Om'ology, UJfiversity of Chicago, Chicago, [L.
Conditioning regimens using alemmzumab (Campath -1H) are 
associated with rates of cytomegalovirus (CMV) infection as high 
as 85-100% in seropositive donor/recipient pairs. High dose acy 
clovir reduces the incidence of CMV viremia. A recent random- 
ized study demonstrated a further eduction in CMV viremia with 
the use of high dose oral valacyclovir after myeloablative trans- 
plantation(Ljungman Blood 2002). We analyzed CMV positive 
donor and/or recipient subjects who underwent an allogeneic 
SCT protocol conditioned with fludarabine 30 mg/m2/d (D-7 to 
D-3), alemtuzumab 20 mg/d (D-7 to D-3), and melphalan 140 
rag/m2 (D-2). All patients initially received acyclovir prophyla:ds. 
CMV infection was defined as any positive CMV test by poly- 
merase chain reaction (PCR), antigen test, or culture. Early (dur- 
ing hospitalization) CMV infection was identified in 6/26 subjects 
at a median of 20 days despite acyclovir prophylaxis. Upon dis- 
charge, the initial nine patients received oral acyclovir (usually 
800mg po qid). After a policy change, the subsequent 11 patients 
received valacyclovir (2 gr po qid). Of the patients who did not 
reactivate in the hospital, 6/9 on oral acyclovir and 3/11 on vala- 
cylovir developed infection, respectively (p= 0.07). One patient 
with CMV viremia and adenovirus in the urine died on day 121 
with an interstitial puhnonary infiltrate. At autopsy, occasional 
alveolar cells were positive for CMV. In smnlnary, oral valacy- 
clovir tended to be more effective than acyclovir at reducing reac- 
tivation after hospital discharge. These data further confirm the 
high incidence of CMV reactivation with alemtuzmnab based con- 
ditioning regimens despite aggressive prophylaxis. Alternative reg- 
imens to reduce early CMV reactivation are needed. 
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PROGNOSTIC FACTORS FOR DAY 100 TRANSPLANT RELATED MOR- 
TALITY (DAY I00 TRM) FOLLOWING HEMATOPOIETIC STEM CELL 
TRANSPLANTATION (HSCT): A RETROSPECTIVE ANALYSIS OF 459 
PATIENTS TRANSPLANTED AT A SINGLE INSTITUTION 
3/lori, S.; TmTaka, ):; Ohashi, K.; Akiyama, H.; I01ku, LI.; Hirmna, 
K.; Sasnki, T.; Sakamaki, H. Tokyo Metropolitan Komagome Hospital, 
Bmzkyo-ku, Tokyo, ffapa*~. 
Objective: To determine predictive factors for non-relapse 
mortality before day100 (day 100-TRM) following HSCT. 
Patients: Consecutive 459 patients (pts) who received HSCT at 
Tokyo Metropolitan Komagome Hospital between January. 1990 
and December 200I. Median age was 43 yrs (range, 0-67) and 277 
were male. Among them, 354 were allograft recipients (211 from 
related, 139 from unrelated and 4 from syngeneic donor) and 
remaining 105 received autologous HSCT. The preparative r gi- 
mens were 12Gy of TBI based (130pts), busulfan based (227pts) 
or others (102pts). Results: Day-100 TRM occurred in 40 pts and 
Kaplan Meier estimate of the incidence was 9.0%. In univariate 
analysis, day-100 TRM occurred more frequently among pts with 
allograft han autograft (10.7% vs 3.1%, Logrank P = 0.024). 
Among pretransplant variables, serum ALT greater than 50 IU/L 
(21.8% vs 6.1%, P < 0.0001) was the most significant factor p e- 
dicting day-100 TRM though Age older than 44 (12.1% vs 8.0%, 
P = 0.16), TBI containing regimen (9.5% vs 8.9%, P = 0.81), vital 
capacity less than predicted (12.9% vs 9.6%, P = 0.34), FEV1.0 
less than 80% of total expiratory volume (9.7% vs 8.9%, P - 0.93) 
or ejection fraction less than 60% (12.4% vs I1.6%, P = 0.80) 
were not significantly associated with day 100 TRM. In Cox 
regression model, allograft and serum ALT were independent 
predictors adjusted for other factors. Conclus ion:  High serum 
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ALTERNATE DAY GANCICLOVIR/FOSCARNET (GAN/FOS) FOR 
CYTOMEGALOVIRUS PROPHYLAXIS IN AT RISK ALLOGENEIC STEM 
CELL TRANSPLANT RELATED AND UNRELATED RECIPIENTS IS 100% 
EFFECTIVE IN PREVENTING CMV INFECTIONS 
S',~et'eck, E.B.; Be~mevtlO,, 0.; Coo~zey, ]s'.3/l.; Herrisom L.; vml de 
UeJ~, C.; f~ischhover, C.; FUolowlzik, K.; Del Toro, G.; B~wlley, ~'i.; 
Geov~'e, D.; Galwi11, ft.; Cairo, M.S. ChildreJ~5" Hospital of Ne~, York 
PT"eskyterim~, Cohmzbia UTziversity, New }~7"te, NY. 
The incidence of cytomegalovirus (CMV) infection post 
AlloSCT has been reduced by prophylactic Gan (56% to 20%) 
(Winston DJ et al, Ann Intern Med 1993; 118:179), but has been 
associated with significant hematopoietic toxicity and secondary 
graft failures. An alternative ffective agent against CMV is Fos 
(Oberg Bet  al, Pharmacol Ther 1989; 40:1213), but is associated 
with nephrotoxicity and electrolyte imbalances. Since both Gan 
and Fos are effective against CMV but have different oxicity pro- 
files, we evaluated the efficacy and safety of alternate day Gan/Fos 
for CMV prophylaxis. MloSCT pts (n-9) that were serologically 
CMV (-) donor/(-) recipient received leukodepleted blood prod- 
ucts (LDBP). 16 pts who were CMV (+) and/or had a CMV (+) 
donor received prophylaxis with IV Fos at 90 mg/kg Q48II alter- 
nating with [V Gan at 5 mg/kg Q48H, initiated at ANC 
_>7507mm 3 until Day +100. M:F 9:7; age 9.5 -+ 6.6 (0.8-18 yr); 1 
APL CR2, 1 Wihns' SD, 1 Hurler's SD, 2 CML CP, 1 AML 
CR2, 1 SAA, 2 ALL CR2, 2 Beta-Thai, 1 ALL CR3, 1 HD PR2, 1 
HD OR2, I ALCL PR, 1 NBL PD; Donors: 5 RPBSC 6/6, 1 
RPBSC 5/6, 3 RBM 6/6, 2 UCB 5/6, 5 UCB 4/6. GVHD prophy- 
laxis: Tacro/MMF. TNC and CD34 for BM/PBSC was 6.6 _+ 6.I 
xl0S/kg and 5.2 -+ 3.1 x 106/kg, and UCB + SD were 4.9 _+ 5.4 
xl07/kg and 2.4 + 1.6 x 10S/kg, respectively. Despite an incidence 
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